Research progress on Chinese materia medica in overcoming EGFR-TKIs acquired drugs resistance through PI3K/Akt/mTOR pathway
10.7501/j.issn.0253-2670.2015.12.026
- Author:
Peng-Tao CAI
1
Author Information
1. Zhejiang Chinese Medical University
- Publication Type:Journal Article
- Keywords:
Acquired drugs resistance;
Chinese materia medica;
Epidermal growth factor receptor tyrosine kinase inhibitors;
Non-small cell lung cancer;
PI3K/Akt/mTOR pathway
- From:
Chinese Traditional and Herbal Drugs
2015;46(12):1849-1852
- CountryChina
- Language:Chinese
-
Abstract:
With in-depth study of the pathogenesis of lung cancer and its biological behaviour, molecular targeted therapy, especially the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) made a breakthrough in non-small cell lung cancer treatment. However, the majority of patients can produce the resistance to EGFR-TKIs after 6 to 12 months treatment, which called acquired drug resistance. PI3K/Akt/mTOR pathway plays an important role in the development of non-small cell lung cancer, this pathway in cancer treatment has been widely studied. Chinese materia medica (CMM) in overcoming EGFR-TKIs resistance has a bright future, In this review, we show the developments on CMM in overcoming EGFR-TKIs acquired drugs resistance through PI3K/Akt/mTOR pathway.
